Company / Accounts Receivable
CRISPR Therapeutics AG Accounts Receivable History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$25.0M
FY2024
5-year range
$0 / $200.0M
FY2020-FY2024
Trend
-87.5%
vs FY2023
Sector context
#88 of 112
Health Care
What the data says
CRISPR Therapeutics AG's accounts receivable of $25M is lower than 79% of companies in the Health Care sector (FY2024). Accounts Receivable has fluctuated over the past 9 years, ranging from $0 in FY2022 to $200M in FY2023.
Based on SEC 10-K filings.
$25M in FY2024 with a 5-year CAGR of +202.3%.
Improved from $0 to $25M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +334.4%
- 5-Year CAGR
- +202.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 112This company $25.0M Sector average $1.1B
▼
-97.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +202.3%, indicating consistent growth.
- In FY2024, accounts receivable decreased 87.5% year-over-year.
- Ranks #88 out of 112 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $25.0M | -87.5% |
| FY2023 | $200.0M | - |
| FY2022 | $0 | -100.0% |
| FY2021 | $305.0K | +111.8% |
| FY2020 | $144.0K | +45.5% |
| FY2019 | $99.0K | +12.5% |
| FY2018 | $88.0K | -96.6% |
| FY2017 | $2.6M | -16.8% |
| FY2016 | $3.2M | +831.3% |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026